Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease

Cristiana Costa Pereira1,2,3*, Cecília Durães4,5*, Rosa Coelho6, Daniela Grácio7, Marco Silva6, Armando Peixoto6, Paula Lago6, Márcia Pereira4,5,9, Telmo Catarino4,5, Salomé Pinho4,5, João Paulo Teixeira1,3, Guilherme Macedo6, Vito Annese10, Fernando Magro2,6,7†

1 Department of Environmental Health, National Institute of Health Dr. Ricardo Jorge, Oporto, Portugal, 2 MedinUP – Centre for Drug Discovery and Innovative Medicines, University of Porto, Oporto, Portugal, 3 EPIUnit – Institute of Public Health, University of Porto, Oporto, Portugal, 4 Ipatimup – Institute of Molecular Pathology and Immunology of the University of Porto, Oporto, Portugal, 5 i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Oporto, Portugal, 6 Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar São João, Oporto, Portugal, 7 Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Oporto, Portugal, 8 Department of Gastroenterology, HSA – Centro Hospitalar do Porto, Oporto, Portugal, 9 Institute for the Biomedical Sciences Abel Salazar, University of Porto, Oporto, Portugal, 10 Emergency Department, Gastroenterology Unit, AOU Careggi, Florence, Italy

* These authors contributed equally to this work.
† fm@med.up.pt

Abstract

Inflammation is the driving force in inflammatory bowel disease (IBD) and its link to oxidative stress and carcinogenesis has long been accepted. The antioxidant system of the intestinal mucosa in IBD is compromised resulting in increased oxidative injury. This defective antioxidant system may be the result of genetic variants in antioxidant genes, which can represent susceptibility factors for IBD, namely Crohn’s disease (CD) and ulcerative colitis (UC). Single nucleotide polymorphisms (SNPs) in the antioxidant genes SOD2 (rs4880) and GPX1 (rs1050450) were genotyped in a Portuguese population comprising 436 Crohn’s disease and 367 ulcerative colitis patients, and 434 healthy controls. We found that the AA genotype in GPX1 is associated with ulcerative colitis (OR = 1.93, adjusted P-value = 0.037). Moreover, we found nominal significant associations between SOD2 and Crohn’s disease susceptibility and disease subphenotypes but these did not withstand the correction for multiple testing. These findings indicate a possible link between disease phenotypes and antioxidant genes. These results suggest a potential role for antioxidant genes in IBD pathogenesis and should be considered in future association studies.

Introduction

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) characterized by inflammation of the intestinal mucosa triggered by the action of...
environmental factors in genetically predisposed individuals [1]. The accepted notion is that the two major classifications of inflammatory bowel disease (IBD), known as Crohn’s disease (CD) and ulcerative colitis (UC), are indeed distinct entities and have different causes and discrete mechanisms of tissue inflammation and damage. UC results in inflammation and ulcerations in the mucosal lining of the colon and rectum [2–6]. Crohn’s disease differs in that it may result in inflammation deeper within the intestinal wall (transmural) and can occur in any parts of the digestive system (the mouth, esophagus, stomach, duodenum, small intestine, colon and rectum). Further, CD may also involve other organs outside the GI system through fistulization [7, 8].

Reactive oxygen species (ROS) have been suggested as key molecules in mediating the tissue injuries promoted by the inflammatory processes occurring in IBD [9, 10], and oxidative stress has been recognized as a potential etiological factor for IBD [11]. The detrimental effects of oxidative stress may be promoted and/or exacerbated by impairments of cellular antioxidant systems. The activation of inflammatory cells and consequent oxidative stress are mechanisms that have already been associated with carcinogenic processes, with 25% of all cancer cases worldwide attributed to chronic inflammation [12]. Recent reports refer 1.9- and 2.4-fold increased risk for CRC among CD and UC patients, respectively [13].

The antioxidant defence systems protect cells against ROS by regulating their intracellular concentrations through the activity of a number of enzymes, including superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPX1). These two enzymes integrate a common detoxification pathway, in which SOD2 (a tetrameric manganese-containing enzyme expressed in mitochondria) first catalyses the dismutation of superoxide anion to hydrogen peroxide and oxygen. The GPX1 enzyme (a cytosolic and ubiquitous selenoenzyme) catalyses the subsequent conversion of hydrogen peroxide to water and oxygen [14]. Their combined action promotes the detoxification of mitochondrial ROS and a balance is expected to exist between these two enzymes, as a deranged activity would result in the accumulation of toxic levels of hydrogen peroxide in the cells [15]. Genetic polymorphisms can modify the activity of these critical enzymes and thus promote imbalances in the cellular oxidative burden. Diseases such as diabetic nephropathy, cardiomyopathy, Behcet’s disease, and various cancers have already been associated with polymorphisms in antioxidant genes [16]. Genetic polymorphisms in SOD2 have also been referred [17] as a potential mechanism interfering in the pharmaco-response of cells exposed to methotrexate (MTX), an immunomodulator commonly prescribed to IBD patients, and an interdependent mechanism of action between SOD2 and GPX1 has been suggested, indicating that these genes could also have an important role for therapeutic management.

Genome wide association studies (GWAS) have identified more than 200 genetic risk loci for IBD [18, 19] but only few were associated with clinical phenotype [20, 21]. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations [19]. Moreover, several genetic polymorphisms have already been linked to IBD etiopathogenesis and to response to therapy [22–24]. Based on the described interactions between inflammation, ROS and oxidative damage, this study aimed to assess the association between IBD (CD and UC) and polymorphisms in the antioxidant genes SOD2 (rs4880, c.47T>C, Val16Ala) and GPX1 (rs1050450, c.596C>T, Pro198Leu). The association of these polymorphisms with IBD has not been studied before.

**Materials and Methods**

**Population**

The study comprised 803 IBD patients (436 CD and 367 UC) and 434 controls (Table 1). The control group included 434 unmatched samples obtained from unrelated healthy blood donors.
This group consisted of permanent residents in the catchment area of Hospital of S. João (Porto, Portugal), selected during the assembling of the EpiPorto cohort [25]. Enrollment of participants was performed under approval of Centro Hospitalar S. João ethic committee (Comissão de Ética para a Saúde do Centro Hospitalar S. João) and included written informed consent for data and DNA usage, obtained by

Table 1. Clinical characteristics of patients with Crohn’s disease and ulcerative colitis.

| Patients characteristics | Crohn’s disease | ulcerative colitis |
|-------------------------|----------------|-------------------|
|                         | n   | %       | n   | %       |
| Total                   | 436 | -       | 367 | -       |
| Family history of IBD (yes/no*) | 37/348 | 9.6/90.4 | 16/231 | 6.5/93.5 |
| Sex (male/female)       | 225/211 | 51.6/48.4 | 162/205 | 44.1/55.9 |
| Smoking habits          | -   | -       | -   | -       |
| Never                   | 189 | 46.2    | 222 | 63.8    |
| Former                  | 108 | 26.4    | 91  | 26.2    |
| Current                 | 112 | 27.4    | 35  | 10.1    |
| Age at diagnosis        | -   | -       | -   | -       |
| A1 (<17 years)          | 56  | 12.8    | 14  | 3.8     |
| A2 (17–40 years)        | 306 | 70.2    | 215 | 58.6    |
| A3 (>40)                | 74  | 17.0    | 138 | 37.6    |
| Location                | 436 | -       | na  | -       |
| L1* (ileal)             | 195 | 44.8    | na  | -       |
| L2 (colonic)            | 60  | 13.8    | na  | -       |
| L3 (ilealcolon)         | 180 | 41.4    | na  | -       |
| L4 (L1+L2+L3)* (involvement of the upper digestive tract) | 47  | (10.8) | na  | -       |
| Location                | na  | -       | 364 | -       |
| E1* (proctitis + rectosigmoid) | na  | -       | 134 | 36.8    |
| E2 (distal)             | na  | -       | 101 | 27.8    |
| E3 (pancolitis)         | na  | -       | 129 | 35.4    |
| Behaviour               | 431 | -       | na  | -       |
| B1* (nonstricturing, nonpenetrating) | 187 | 43.4 | na  | -       |
| B2 (stricturing)        | 90  | 20.9    | na  | -       |
| B3 (penetrating)        | 154 | 35.7    | na  | -       |
| P (B1+B2+B3)* (perianal disease) | 41  | (9.5)  | na  | -       |
| Rectal involvement (yes/no*) | 229/207 | 52.5/47.5 | 198/38 | 83.9/16.1 |
| Colonic involvement (yes/no*) | 226/208 | 52.1/47.9 | 23/342 | 6.3/93.7 |
| Abdominal surgery (yes/no*) | 53/383 | 12.2/87.8 | 7/230 | 3.0/97.0 |
| Extraintestinal manifestations (yes/no*) | 398/36 | 91.7/8.3 | 225/141 | 61.5/38.5 |
| Previous ongoing corticosteroids (yes/no*) | 189/243 | 43.8/56.3 | 81/206 | 28.2/71.8 |
| Steroid dependency (yes/no*) | 11/422 | 2.5/97.5 | 26/261 | 9.1/90.9 |
| Steroid resistance (yes/no*) | 359/50 | 87.8/12.2 | 130/236 | 35.5/64.5 |
| Need for immunosuppressant (yes/no*) | 229/138 | 62.4/37.6 | 72/51 | 58.5/41.5 |
| Response to immunosuppressant (yes/no) | 198/42 | 82.5/17.5 | 50/19 | 72.5/27.5 |

* Represents the reference in the case-case association studies;
** For L4 and P phenotypes the reference is absence of phenotype;
na: not applicable

(mean age 47.2±18.7 years; female: male ratio: 1.4:1).
trained personnel (nurses and doctors) upon collection. The participants included did not present any apparent infectious and/or chronic disorders.

The IBD group included 436 CD and 237 UC patients enrolled at Centro Hospitalar São João, Porto, Portugal; these patients attended their routine IBD specialist medical appointment and all were prospectively followed-up in a national database from Portuguese IBD group (GEDII, https://gediibasedados.med.up.pt/). An additional 130 UC patients were enrolled at Centro Hospitalar do Porto, Hospital de Santo António (CHP-HSA), Porto, Portugal, prospectively followed at the same hospital. The diagnosis of IBD was made according to the ECCO (European Crohn’s and Colitis Organisation) guidelines for CD [26] and UC [27] diagnosis, and the Lennard-Jones criteria [28]. Information on patients’ characteristics was obtained, namely smoking habits, age at diagnosis, years of follow-up, location and behaviour of disease, extra-intestinal manifestations, rectal and colonic involvement, previous abdominal surgery, previous corticotherapy, steroid dependency and resistance, need for immunosuppressant, response to immunosuppressant and response to biologic therapy (Table 1). Location, behaviour and age at diagnosis, were classified according to the Montreal Classification [29]. Patients were defined as steroid-dependent when incapable to reduce steroids below the equivalent of prednisolone of 10mg per day within three months of starting steroids without recurrent active disease or disease relapse within three months of stopping steroids. The steroid resistance was considered as the presence of active disease despite of a prednisolone dose of up to 0.75mg/kg per day over a period of four weeks [30]. Patients who had treatment with azathioprine, or methotrexate were considered in the group of ‘need for immunosuppressant’. The ‘response to immunosuppressant’ was defined as positive when long-term sustained improvement of the symptoms was achieved, lasting at least one year without any further modifications in the therapeutic regime; the response was considered negative whenever no symptom improvement was verified after three months of full dose with azathioprine or methotrexate or by decision of the physician to add steroids or biologic therapy (anti-TNFα) or to refer for surgery. The ‘response to biologic therapy’ was defined as positive when long-term sustained improvement of the symptoms lasting at least one year without any further modifications in the therapeutic regimen was observed; failure of the therapeutic regimen was defined by an absence of improvement of the symptoms of disease and by decision of the physician to add steroids, add an immunosuppressant, switch to an alternative biologic therapy medication or to refer for surgery. S1 Table shows the clinical characteristics defining the phenotypes tested for association (reference categories used in the association analyses are marked with an asterisk). The Ethics Committee of both institutions—Comissão de Ética para a Saúde do Centro Hospitalar São João, and Comissão de Ética para a Saúde do Centro Hospitalar do Porto—approved the protocol and all patients or their legal guardians gave their written informed consent, complying with the principles laid down in the Declaration of Helsinki.

SNP selection and genotyping

We identified two potential functional polymorphisms involved in antioxidant pathways—SOD2 A/G (rs4880) and GPX1 G/A (rs1050450)—whose main effects have already been described for other conditions. These SNPs have a reported minor allele frequency of ≥0.1 for the European Caucasian population (S2 Table). Patients’ and controls’ genomic DNA was isolated from blood using the QIAcube system and the QIAamp DNA Blood Mini QIAcube Kit (Qiagen, Venlo, The Netherlands) following the supplier’s instructions. The SNPs were genotyped on the complementary DNA strand using TaqMan Pre-Designed SNP Genotyping Assay (Life Technologies, Carlsbad, CA, USA) (S3 Table). DNA amplification and allelic discrimination were performed according to product specifications with the ABI 7500 Fast real-
time PCR system (Applied Biosystems, Carlsbad, USA). Cases and controls were randomized during genotyping and 5% of the samples were genotyped in duplicate to assess the genotyping error rate. Concordance of genotypes was 100%.

Statistical analysis
Genotyping results were evaluated with the SNPassoc 1.6–0 package in the statistical software suite R. Compliance of alleles at individual loci with Hardy-Weinberg equilibrium was measured at the level of the control group using a $\chi^2$ test (P-value<0.05). Power calculations conducted before the study indicated there was more than 80% power to detect significant associations of OR between 1.3 and 2.0 for both SNPs and both disease groups. Calculations were performed using CaTS software with the following settings: SOD2 (rs4880): MAF = 0.47, OR = 1.25–2.00, CD and UC prevalence Portugal = 0.07% [31], CD case/control = 340/330, UC case/control = 370/330; GPX1 (rs1050450): MAF = 0.34, OR = 1.25–2.00, CD and UC prevalence Portugal = 0.07%[31], case/control = 340/330, UC case/control = 370/330. A post-hoc power analysis showed that the power to detect significant associations is 100% for both disease groups since the ORs observed fall within the 1.5–2.0 range (or the equivalent 0.5–1.0 range).

Comparison of genotype frequencies between groups defined by status (patients vs. controls) and clinical characteristics were assessed by unconditional logistic regression (level of significance set to P-value<0.05) using the SNPassoc library in R and SPSS 23 (IBM SPSS statistics). The models included adjustment by sex and age. The codominant and recessive models of inheritance were considered. Odds ratios (OR) with respective confidence intervals (95% CI) were calculated for the allele (one copy or genotype) with minor frequency. The association of SNPs with CD and UC clinical characteristics was subsequently assessed using case-case analyses (S3 Table). The IBD phenotypes and reference categories are defined in Table 1. The Bonferroni correction was used to adjust for multiple testing in the analysis of overall association of SNPs with CD and UC (Table 2) and in the case-case analysis (Table 3). The correction was applied separately to each disease group.

Results
Genotypic frequencies and overall association with CD and UC
We genotyped two SNPs in antioxidant enzyme genes (SOD2 and GPX1). In the control group, the frequencies of all SNPs did not deviate significantly from those expected under Hardy-Weinberg equilibrium (P>0.05). Table 2 summarizes the genotype frequencies for the SNPs rs4880 in SOD2 and rs1050450 in GPX1, and overall associations with CD and UC (OR, 95% CI and respective P-values).

Based on the two models analysed—codominant and recessive—SNP rs1050450 in GPX1 achieved nominal significant association with UC with $P$-values of 0.006, in the codominant, and 0.012, for the recessive model. In the codominant model the homozygous AA showed an OR (CI) of 1.93 (1.20–3.12) and in the recessive model an OR (CI) of 1.78 (1.13–2.80) is observed. After correction for multiple testing (Bonferroni correction) the homozygous AA genotype of GPX1 (rs1050450) withstood the association with UC with an adjusted P-value of 0.037. SNP rs4880 in SOD2 achieved a nominal significant association with CD in both models analysed, codominant and recessive, with $P$-values of 0.013 and 0.033, respectively. The homozygous GG showed an OR (CI) of 0.57 (0.37–0.89) in the codominant model and an OR (CI) of 0.66 (0.45–0.97) in the recessive model. These associations were lost when corrected for multiple testing. The SNPs were also considered for analysis with CD and UC phenotypes (genotype frequencies are reported in S4 and S5 Tables, respectively).
Bonferroni correction for the genotype-phenotype case-case analyses in CD established a p-value of 0.00063 (Table 3), and none of the associations found could remain significant. Nevertheless, nominal p-values were found significant for some phenotypes, as follows:

**Genotype association with CD phenotypes**

Under the recessive model (Table 3), we found significant associations between SNP rs4880 in SOD2 and 'rectal involvement' [OR (CI) = 1.83 (1.03–1.98), \( P = 0.034 \)], and 'colonic involvement' [OR(CI) 1.93 (1.15–3.22), \( P = 0.011 \)]. In the codominant model (Table 3), SOD2 homozygous GG was associated with 'rectal involvement' [OR (CI) = 2.08 (1.09–3.96), \( P = 0.026 \)].

**Genotype association with UC phenotypes**

Within UC, under the recessive model we found significant associations between SNP rs4880 in SOD2 and location (E2 vs E1) [OR (CI) = 0.50 (0.26–0.96), \( P = 0.032 \)] (data not shown in table).

**Combined genotypes and risk profiles**

Joint effects of the risk genotypes observed for CD and UC phenotypes have been assessed, however, no significant associations were found (\( P > 0.05 \) for all the combinations tested; data not shown).

---

**Table 2. Genotypic frequencies and overall association of genetic variants in SOD2 and GPX1 with Crohn’s disease and ulcerative colitis.**

| Locus       | Model | Controls n = 434 | Crohn’s disease n = 436 | OR (95% CI) | P-value | P-value adjusted | Ulcerative colitis n = 367 | OR (95% CI) | P-value | P-value adjusted |
|-------------|-------|------------------|-------------------------|-------------|---------|------------------|----------------------------|-------------|---------|------------------|
| SOD2 rs4880 |       | n = 426          | n = 435                 |             |         |                  | n = 367                    |             |         |                  |
| AA*         |       | 119 (27.9)       | 142 (32.6)              | 1.00        |         |                  | 102 (27.8)                | 1.00        |         |                  |
| GA          |       | 198 (46.5)       | 214 (49.2)              | 0.79 (0.55–1.13) | 0.193   | 1.00             | 184 (50.1)                | 1.07 (0.75–1.51) | 0.700   | 1.00             |
| GG          |       | 109 (25.6)       | 79 (18.2)               | 0.57 (0.37–0.89) | 0.013   | 0.077            | 81 (22.1)                 | 0.89 (0.59–1.34) | 0.547   | 1.00             |
| A carrier*  |       | 317 (74.4)/109 (25.6) | 356 (81.8)/79 (18.2) | 0.66 (0.45–0.97) | 0.033   | 0.197            | 286 (77.9)/81 (22.1) | 0.85 (0.60–1.20) | 0.366   | 1.00             |

| GPX1 rs1050450 |       | n = 428          | n = 430                 |             |         |                  | n = 367                    |             |         |                  |
| GG*          |       | 199 (46.5)       | 191 (44.4)              | 1.00        |         |                  | 146 (39.8)                | 1.00        |         |                  |
| GA           |       | 187 (43.7)       | 187 (43.5)              | 0.96 (0.69–1.34) | 0.802   | 1.00             | 164 (44.7)                | 1.18 (0.88–1.61) | 0.277   | 1.00             |
| AA           |       | 42 (9.8)         | 52 (12.1)               | 1.39 (0.80–2.40) | 0.242   | 1.00             | 57 (15.5)                 | 1.93 (1.20–3.12) | 0.006   | 0.037            |
| G carrier*   |       | 386 (90.2)/42 (9.8) | 378 (87.9)/52 (12.1)   | 1.39 (0.83–1.38) | 0.210   | 1.00             | 310 (84.5)/57 (15.5) | 1.78 (1.13–2.80) | 0.012   | 0.070            |

* Reference;

ORs and 95% CIs were calculated considering the codominant and recessive models, adjusted for gender and age; bold font indicates nominally significant results; \textbf{p-value cutoff = 0.0083} (after Bonferroni correction applied separately to each disease group); SNPs were genotyped on the complementary DNA strand.

doi:10.1371/journal.pone.0169102.t002
The characterization of susceptibility genes in IBD is expected to bring benefit for the identification of primary pathogenic pathways, and possible environmental drivers, as well as new therapeutic targets. To clarify whether polymorphisms in antioxidant enzyme genes were associated with IBD (CD and UC) we conducted case-control and case-case studies for two SNPs in antioxidant genes (**SOD2** Val16Ala and **GPX1** Pro198Leu). To our best knowledge, this is the first study investigating the association between these genetic variants and IBD pathogenesis. Among the already published GWAS studies in IBD the only reference found related to these two genes is for GPX1 that has been suggested [32] to be in linkage disequilibrium with macrophage stimulating protein-1 (**MST1**); the authors propose that SNP rs1050450 (c.596C>T) in **GPX1** is the pathophysiologic link between IBD locus and IBD, rather than the macrophage stimulating protein-1 (**MST1**), as previously described.

In our study the allele A in **GPX1** (rs1050450) significantly associated with UC in the recessive model with an ORs of 1.93, and an adjusted P-value of 0.037. Antioxidant enzymes maintain cellular redox homeostasis. Glutathione peroxidase (GPX) is a selenoenzyme that catalyses the breakdown of hydrogen peroxide (H₂O₂), and other organic peroxides, into water (H₂O) and oxygen (O₂). GPX1 is cytosolic and produced in all tissues. The SNP rs1050450 (or **GPX1** Pro198Leu) has been studied extensively in human disease and has already been linked to cancer risk [33], and oxidative stress related diseases [34]. The Leu198 variant results in a 10% reduced enzyme activity compared with the Pro198 variant [35], interfering with the overall capacity to respond to oxidative damage [34]. Individuals with reduced GPX1 activity exhibit an increased incidence of oxidative stress-related diseases such as breast, Table 3. Association of SNPs in the antioxidant system genes **SOD2** and **GPX1** with Crohn’s disease clinical characteristics.

| Locus | SNP / Model | Ilealcolonic (L3)** | Rectal involvement | Colonic involvement | Responds to biologics |
|-------|-------------|---------------------|--------------------|--------------------|----------------------|
|       |             | OR (95% Cl) | P-value | OR (95% Cl) | P-value | OR (95% Cl) | P-value | OR (95% Cl) | P-value |
| **SOD2**rs4880 | AA          | 1.00       | 1.00     | 1.00     | 1.00     | 1.00     | 1.00     | 1.00     | 1.00      |
|         | GA          | 0.82 (0.41–1.65) | 0.577 | 1.23 (0.72–2.10) | 0.457 | 0.84 (0.55–1.30) | 0.442 | 1.48 (0.65–3.35) | 0.347 |
|         | GG          | 0.71 (0.31–1.63) | 0.422 | 2.08 (1.09–3.96) | 0.026 | 1.74 (0.98–3.10) | 0.059 | 1.08 (0.37–3.10) | 0.890 |
|         | A carrier* vs. GG | 0.80 (0.40–1.63) | 0.546 | 1.83 (1.06–3.16) | 0.034 | 1.93 (1.15–3.22) | 0.011 | 0.83 (0.34–2.03) | 0.682 |
| **GPX1**rs1050450 | GG*         | 1.00       | 1.00     | 1.00     | 1.00     | 1.00     | 1.00     | 1.00     | 1.00      |
|         | GA          | 2.70 (1.39–5.24) | 0.003 | 1.01 (0.62–1.63) | 0.965 | 0.86 (0.57–1.30) | 0.132 | 1.57 (0.72–3.43) | 0.26      |
|         | AA          | 1.81 (0.66–4.95) | 0.250 | 0.61 (0.26–1.40) | 0.093 | 0.62 (0.33–1.16) | 0.475 | 3.10 (1.10–8.70) | 0.032 |
|         | G carrier* vs. AA | 1.17 (0.44–3.10) | 0.750 | 0.60 (0.27–1.34) | 0.196 | 0.66 (0.37–1.20) | 0.175 | 2.42 (0.96–6.10) | 0.071 |

* Reference; phenotype reference categories were defined as in Table 1; ** Reference category is “colonic” location; ORs and 95% CIs were calculated considering the recessive and codominant models, adjusted for gender and age; Bold font indicates nominally significant results; P-value cutoff = 0.00063 (after Bonferroni correction applied to 80 tests performed in the case-case analysis in the CD group); SNPs were genotyped on the complementary DNA strand.

doi:10.1371/journal.pone.0169102.t003

Discussion

The characterization of susceptibility genes in IBD is expected to bring benefit for the identification of primary pathogenic pathways, and possible environmental drivers, as well as new therapeutic targets. To clarify whether polymorphisms in antioxidant enzyme genes were associated with IBD (CD and UC) we conducted case-control and case-case studies for two SNPs in antioxidant genes (**SOD2** Val16Ala and **GPX1** Pro198Leu). To our best knowledge, this is the first study investigating the association between these genetic variants and IBD pathogenesis. Among the already published GWAS studies in IBD the only reference found related to these two genes is for GPX1 that has been suggested [32] to be in linkage disequilibrium with macrophage stimulating protein-1 (**MST1**); the authors propose that SNP rs1050450 (c.596C>T) in **GPX1** is the pathophysiologic link between IBD locus and IBD, rather than the macrophage stimulating protein-1 (**MST1**), as previously described.

In our study the allele A in **GPX1** (rs1050450) significantly associated with UC in the recessive model with an ORs of 1.93, and an adjusted P-value of 0.037. Antioxidant enzymes maintain cellular redox homeostasis. Glutathione peroxidase (GPX) is a selenoenzyme that catalyses the breakdown of hydrogen peroxide (H₂O₂), and other organic peroxides, into water (H₂O) and oxygen (O₂). GPX1 is cytosolic and produced in all tissues. The SNP rs1050450 (or **GPX1** Pro198Leu) has been studied extensively in human disease and has already been linked to cancer risk [33], and oxidative stress related diseases [34]. The Leu198 variant results in a 10% reduced enzyme activity compared with the Pro198 variant [35], interfering with the overall capacity to respond to oxidative damage [34]. Individuals with reduced GPX1 activity exhibit an increased incidence of oxidative stress-related diseases such as breast,
colon, prostate, bladder and lung cancers, coronary artery disease, and also, low bone mineral density [36] and osteoarthropathy [37].

Studies using genetically altered mice with reduced GPX1 activity have shown a link to chronic and acute gastrointestinal inflammation [38]. In this study, we found that the variant with lower activity GPX1 198Leu associates with UC (OR 1.93, \( P = 0.006 \)). In the CD group, a 3.1-fold increased odds for ‘responding to biologics’ was found for carriers of the homozygous variant Leu198Leu (\( P = 0.03 \)). These findings along with the recent observation that SNP rs1050450 in GPX1 is the pathophysiological link for IBD locus 12 [32], suggest that this gene is a good candidate as a biomarker for disease and treatment management purposes.

The SOD2 enzyme, also known as manganese superoxide dismutase (MnSOD), is one of the major antioxidant defence systems against mitochondrial superoxide radicals [39] and is one of the first in a chain of enzymes to mediate the ROS generated by the partial reduction of \( \text{O}_2 \) to hydrogen peroxide (\( \text{H}_2\text{O}_2 \)). The MnSOD expression has been suggested as a potential biomarker in UC for predicting disease activity and severity [40]. While the valine-containing SOD2 (rs4880) is partially arrested in the inner mitochondrial membrane, the alanine-containing SOD2 (rs4880) is actively targeted to the mitochondrial matrix resulting in a 30–40% increase in SOD2 activity for the Ala16Ala variant, due to more efficient transport of the protein into the mitochondrial matrix [41] and to a 4-fold higher and stable mRNA expression [42]. Crawford et al. (2012) [16] reviewed 79 studies addressing a potential link between the SOD2 Val16Ala genotype and various diseases or disorders, and almost half of those studies reported relationships with various types of cancers, e.g. gastric, lung, prostate, bladder and breast, to diabetes type I, nephropathy, chronic kidney disease, and to chemotherapy responses. The Ala16Ala genotype is generally associated with a protective effect, yet important differences are described in the literature, which indicates a complex role for the presence of risk allele C. Also, it has been suggested that SOD2 16Val variant is associated with an increased production of pro-inflammatory cytokines [43], and that its expression can be modulated through NF-kB binding to the promoter region of the gene [44].

In this study, although significances were lost after correction for multiple testing, nominal significant associations suggest a potential protective role regarding CD. Also, SOD2 Ala16Ala variant in the CD group presented a 2.08-fold risk for rectal involvement (\( P = 0.026 \)), and in the recessive model, it also presented 1.93 odds for colonic involvement. These findings might indicate that although this variant is uncommon among CD patients, when present it confers some susceptibility for rectal and colonic involvement. We suggest that overall, this gene might be implicated in disease location, and the fact that the pro-inflammatory prone variant (16Val) is more common among CD, the variant 16Ala is associated with colonic involvement in CD. Also, the referred putative effects of SOD2 in inflammatory pathways, together with the fact that SOD2 expression can be induced by dietary intake of antioxidants [45], indicate a potential therapeutic targeting for this gene as well as for dietary intervention benefits.

**Conclusion**

This aim of this study was to explore possible associations between IBD pathogenesis (CD and UC) and gene polymorphisms implicated in other oxidative stress conditions, taking into account several clinical characteristics. We found a significant association between the variant GPXI (rs1050450) and UC. This association needs to be tested in an independent cohort to validate these findings. Genetic association studies support the idea that disease location is genetically determined and many important loci that could explain disease
heterogeneity are still undetermined [20]. Also, the work of Hauser et al. [32] recently published suggesting a pathophysiological role for \( GPX1 \) (rs1050450) is as well suggested with our findings. Overall, our results point out to a potential role of antioxidant genes in IBD pathogenesis.

Supporting Information

S1 File. Dataset. (XLSX)

S1 Table. Phenotype categories and number of tests performed for Crohn’s disease and ulcerative colitis case-case analysis (according to the clinical characteristics described in Table 1). (PDF)

S2 Table. Characteristics of the SNPs genotyped. (PDF)

S3 Table. TaqMan SNP genotyping assay details. (PDF)

S4 Table. Summary of genotypic frequencies of SNPs in, \( SOD2 \), and \( GPX1 \) [n (%)] in the Crohn’s disease group. Cases subdivided according to location, rectal involvement, colonic involvement and response to biologics. (PDF)

S5 Table. Summary of genotypic frequencies of SNPs in, \( SOD2 \), and \( GPX1 \) [n (%)] in the ulcerative colitis group. Cases subdivided according to location. (PDF)

Author Contributions

Conceptualization: CCP FM.

Data curation: CCP CD FM.

Formal analysis: CCP CD FM.

Funding acquisition: CCP.

Investigation: CCP CD RC DG MS AP PL MP TC SP FM.

Methodology: CCP CD FM.

Project administration: FM.

Resources: RC DG MS AP PL MP TC FM.

Supervision: FM.

Validation: CD VA.

Visualization: CCP CD FM.

Writing – original draft: CCP CD.

Writing – review & editing: CCP CD JPT GM VA FM.
References

1. Abraham C, Cho JH. Inflammatory Bowel Disease. New England Journal of Medicine. 2009; 361(21):2066–78. doi: 10.1056/NEJMra0804647 PMID: 19923578

2. Podolsky DK. Inflammatory Bowel Disease. New England Journal of Medicine. 2002; 347(6):417–29. doi: 10.1056/NEJMra020831 PMID: 12167685

3. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn’s disease. Immunological reviews. 2005; 206:277–95. Epub 2005/07/29. doi: 10.1111/j.0105-2896.2005.00293.x PMID: 16048555

4. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunological reviews. 2005; 206:296–305. Epub 2005/07/29. doi: 10.1111/j.0105-2896.2005.00286.x PMID: 16048556

5. Hyams JS. Crohn’s disease in children. Pediatric clinics of North America. 1996; 43(1):255–77. Epub 1996/02/01. PMID: 8596683

6. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. The Journal of pediatrics. 1996; 129(1):81–8. Epub 1996/07/01. PMID: 8757566

7. Nosti PA, Stahl TJ, Sokol AI. Surgical repair of rectovaginal fistulas in patients with Crohn’s disease. European journal of obstetrics, gynecology, and reproductive biology. 2013; 171(1):166–70. Epub 2013/09/10. doi: 10.1016/j.ejogrb.2013.08.011 PMID: 24011379

8. Nielsen OH, Rogler G, Hahnloser D, Thomsen OO. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009; 6(2):92–106. Epub 2009/01/21. doi: 10.1038/ncpgasthep1340 PMID: 19153563

9. Jurjus A, Eid A, Al Kattar S, Zeenny MN, Gerges-Geagea A, Haydar H, et al. Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links. BBA clinical. 2016; 5:16–24. Epub 2016/04/07. doi: 10.1016/j.bbaclei.2015.11.002 PMID: 27051585

10. Alzoghaibi MA. Concepts of oxidative stress and antioxidant defense in Crohn's disease. World J Gastroenterol. 2013; 19(39):6537–49. doi: 10.3748/wjg.v19.i39.6540 PMID: 24151379

11. Pereira C, Gracio D, Teixeira JP, Magro F. Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(10):2403–17. Epub 2015/07/21. PMID: 26193347

12. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Current pharmaceutical design. 2012; 18(26):3831–52. Epub 2012/05/29. PMID: 22632748

13. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11):945–65. Epub 2015/08/22. doi: 10.1093/ecco-jcc/jjv141 PMID: 26294789

14. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002; 33(3):337–49. Epub 2002/07/20. PMID: 12126755

15. Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology. 2001; 120(6):1468–74. Epub 2001/04/21. PMID: 11313317

16. Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene. 2012; 501(2):89–103. Epub 2012/04/25. doi: 10.1016/j.gene.2012.04.011 PMID: 22525041

17. Barbisian F, Motta JdR, Trott A, Azzolin V, Dornelles EB, Marcon M, et al. Methotrexate-Related Response on Human Peripheral Blood Mononuclear Cells May Be Modulated by the Ala16Val-SOD2 Gene Polymorphism. PLoS ONE. 2014; 9(10):e107299. doi: 10.1371/journal.pone.0107299 PMID: 25330300

18. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119–24. http://www.nature.com/nature/journal/v491/n7422/abs/nature11582.html#supplementary-information. doi: 10.1038/nature11582 PMID: 23128233

19. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9):979–86. Epub 2015/07/21. doi: 10.1038/ng.3359 PMID: 26192919

20. Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet (London, England). 2016; 387(10014):156–67. Epub 2015/10/23.

21. Alonso A, Domenech E, Julia A, Panes J, Garcia-Sanchez V, Mateu PN, et al. Identification of risk loci for Crohn’s disease phenotypes using a genome-wide association study. Gastroenterology. 2015; 148(4):794–805. Epub 2015/01/06. doi: 10.1053/j.gastro.2014.12.030 PMID: 25557990
22. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(7):390–407. doi: 10.1038/ncpgasthep0528 PMID: 16819502

23. Ladislava B, Michal K, Katerina W, Milan B. Gene Polymorphisms and Inflammatory Bowel Diseases. In: (Ed.) DIS, editor. Inflammatory Bowel Disease. InTech2012.

24. Ackkar JP, Fiocchi C. Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am J Gastroenterol. 2009; 104(7):1734–6. Epub 2009/05/14. doi: 10.1038/ajg.2009.179 PMID: 19436278

25. Ramos E, Lopes C, Barros H. Investigating the Effect of Nonparticipation Using a Population-Based Case—Control Study on Myocardial Infarction. Ann Epidemiol. 2004; 14:437–41. doi: 10.1016/j.annepidem.2003.09.013 PMID: 15246333

26. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4(1):7–27. Epub 2010/12/03. doi: 10.1016/j.crohns.2009.12.003 PMID: 21124288

27. Dignass A, Eliaikim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6(10):965–90. Epub 2012/10/09. doi: 10.1016/j.crohns.2012.09.003 PMID: 23040452

28. Lennard-Jones JE. Classification of inflammatory bowel disease. Scandinavian journal of gastroenterology Supplement. 1989; 170:2–6; discussion 16–9. Epub 1989/01/01. PMID: 2617184

29. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005; 19 Suppl A:5a–36a. Epub 2005/09/10.

30. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010; 4(1):28–62. Epub 2010/12/03. doi: 10.1016/j.crohns.2009.12.002 PMID: 21122489

31. Azevedo LF, Magro F, Portela F, Lago P, Deus J, Cotter J, et al. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. Pharmacoepidemiology and drug safety. 2010; 19(5):499–510. Epub 2010/03/23. doi: 10.1002/pds.20306455

32. Hauser F, Rossmann H, Laubert-Reh D, Wild PS, Zeller T, Muller C, et al. Inflammatory bowel disease (IBD) locus 12: is glutathione peroxidase-1 (GPX1) the relevant gene? Genes Immun. 2015; 16(8):571–5. Epub 2015/09/12. doi: 10.1038/gene.2015.35 PMID: 26355565

33. Hong Z, Tian C, Zhang X. GPX1 gene Pro200Leu polymorphism, erythrocyte GPX activity, and cancer risk. Mol Biol Rep. 2013; 40(2):1801–12. doi: 10.1007/s11033-012-2234-3 PMID: 23073788

34. Meplan C. Selenium and chronic diseases: a nutritional genomics perspective. Nutrients. 2015; 7(5):3621–51. doi: 10.3390/nu7053621 PMID: 25988760

35. Ravn-Haren G, Olsen A, Tjonneland A, Dragsted LO, Nexo BA, Wallin H, et al. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis. 2006; 27(4):820–5. Epub 2005/11/17. doi: 10.1093/carcin/bgi267 PMID: 16287877

36. Mlakar SJ, Osredkar J, Prezelj J, Marc J. The antioxidant enzyme GPX1 gene polymorphisms are associated with low BMD and increased bone turnover markers. Dis Markers. 2010; 29(2):71–80. doi: 10.3233/DMA-2010-0728 PMID: 21045266

37. Xiong YM, Mo XY, Zou XZ, Song RX, Sun WY, Lu W, et al. Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin-Beck disease. Osteoarthritis Cartilage. 2010; 18(6):817–24. doi: 10.1016/j.joca.2010.02.004 PMID: 20178852

38. Chu FF, Esworthy RS, Doroshow JH. Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer. Free Radic Biol Med. 2004; 36(12):1481–95. Epub 2004/06/09. doi: 10.1016/j.freeradbiomed.2004.04.010 PMID: 15182851

39. Ascencio-Montiel I, Parra E., Salgado A., Gomez-Zamudio J., Kumate-Rodriguez J., Escobedo-de-la-Peña J., Cruz M. SOD2 gene Val16Ala polymorphism is associated with macroalbuminuria in Mexican Type 2 Diabetes patients: a comparative study and meta-analysis. BMC Medical Genetics. 2013; 14.

40. Ikumoto T, Hayashi S, Tomita S, Miwa S, Mitomi H, Fujimori T, et al. Manganese superoxide dismutase plays an important role in the inflammatory process and predicts disease severity and activity in patients with ulcerative colitis. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2014; 122:512–7.
41. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics. 2003; 13(3):145–57. Epub 2003/03/06. PMID: 12618592

42. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenetics and genomics. 2005; 15(5):311–9. Epub 2005/05/03. PMID: 15864132

43. Montano MA, da Cruz IB, Duarte MM, Krewer Cda C, da Rocha MI, Manica-Cattani MF, et al. Inflammatory cytokines in vitro production are associated with Ala16Val superoxide dismutase gene polymorphism of peripheral blood mononuclear cells. Cytokine. 2012; 60(1):30–3. Epub 2012/06/13. doi: 10.1016/j.cyto.2012.05.022 PMID: 22688013

44. Li C, Zhou HM. The role of manganese superoxide dismutase in inflammation defense. Enzyme Res. 2011; 2011:387176. doi: 10.4061/2011/387176 PMID: 21977313

45. St Clair D. Manganese superoxide dismutase: genetic variation and regulation. J Nutr. 2004; 134(11):3190s–1s. Epub 2004/10/30. PMID: 15514302